Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Jul. 01, 2011	Jul. 02, 2010
Cash flows from operating activities:
Net income (loss)	$ 18,000	$ (273,000)
Adjustments to reconcile net loss to net cash provided by operating activities
Depreciation	257,000	244,000
Amortization	342,000	406,000
Stock based compensation expense	36,000	18,000
Change in fair value of warrant liability	(492,000)	(54,000)
Changes in operating assets and liabilities:
Accounts receivable - net	(227,000)	(728,000)
Inventories	(287,000)	(149,000)
Prepaid expenses and other assets	33,000	(178,000)
Accounts payable and accrued expenses	(257,000)	820,000
Net cash provided by (used in) operating activities	(577,000)	106,000
Cash flows from investing activities:
Capital expenditures	(368,000)	(182,000)
Patent expenditures	(64,000)	(111,000)
Net cash used in investing activities	(432,000)	(293,000)
Cash flows from financing activities:
Payments on bank term loan	(145,000)	(145,000)
Payments on MEDC/MSF term loan	(169,000)
Payments on related parties debt	(75,000)
Proceeds from exercise of restricted shares		1,000
Proceeds from exercise of stock options	9,000
Net cash used in financing activities	(380,000)	(144,000)
Net decrease in cash and cash equivalents	(1,389,000)	(331,000)
Cash and cash equivalents at beginning of period	4,744,000	1,762,000
Cash and cash equivalents at end of period	3,355,000	1,431,000
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	62,000	76,000
Non-cash financing activities:
Conversion of accrued MEDC loan interest to common stock		$ 562,000